Civic Intelligence

Translational Testing and Training

990 • Fiscal year 2011 • EIN 80-0079841

Jan 01, 2011 to Dec 31, 2011

Atlanta, GA
Siviq Scores

Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.

Liabilities / Assets

35th percentile

0.14x

Higher debt load relative to assets than 35% of similar nonprofits.

2011 filings • 501(c)3 • $10M-$25M nonprofits • Source year 2011

Liabilities / Revenue

63rd percentile

0.41x

Higher debt load relative to revenue than 63% of similar nonprofits.

2011 filings • 501(c)3 • $10M-$25M nonprofits • Source year 2011

Net Margin

4th percentile

-74%

Higher net margin than 4% of similar nonprofits.

2011 filings • 501(c)3 • $10M-$25M nonprofits • Source year 2011

Top Officer Pay

Score unavailable

No value available

This filing does not contain officer compensation rows.

Source year 2011

Asset Growth

20th percentile

-4.4%

Faster asset growth than 20% of similar nonprofits.

2011 filings • 501(c)3 • $10M-$25M nonprofits • Annualized from 2010 to 2011

Revenue Growth

Score unavailable

No value available

No earlier valid filing was available within the previous three public years.

Source year 2011

Assets

Down

$23,494,807

Down $1,086,676 (-4.4%) from 2010

Net Assets

Up

$20,186,096

Up $22,165,465 (+1120%) from 2010

Liabilities

Down

$3,308,711

Down $23,252,141 (-88%) from 2010

Revenue

$8,032,339

No earlier filing loaded for comparison.

Expenses

Up

$13,965,618

Up $1,941,889 (+16%) from 2010

Net Income

-$5,933,279

No earlier filing loaded for comparison.

Historical Trend

Balance Sheet Trend

The highlighted filing sits inside the broader history for assets, liabilities, and net assets.

$30M$20M$10M$0-$10MAssets 2010: $24,581,483Liabilities 2010: $26,560,852Net Assets 2010: -$1,979,3692010Assets 2011: $23,494,807Liabilities 2011: $3,308,711Net Assets 2011: $20,186,0962011Assets 2017: $10,306,660Liabilities 2017: $998,240Net Assets 2017: $9,308,4202017Assets 2018: $9,641,141Liabilities 2018: $1,788,833Net Assets 2018: $7,852,3082018Assets 2019: $11,185,137Liabilities 2019: $3,174,365Net Assets 2019: $8,010,7722019Assets 2020: $8,937,762Liabilities 2020: $2,886,140Net Assets 2020: $6,051,6222020Assets 2021: $8,359,522Liabilities 2021: $3,417,176Net Assets 2021: $4,942,3462021Assets 2022: $9,085,833Liabilities 2022: $4,035,917Net Assets 2022: $5,049,9162022Assets 2023: $12,870,420Liabilities 2023: $8,628,805Net Assets 2023: $4,241,6152023Assets 2024: $30,174Liabilities 2024: $0Net Assets 2024: $30,1742024Assets 2025: $81,612Liabilities 2025: $9,185Net Assets 2025: $72,4272025

Highlighted filing

2011

Assets$23,494,807
Liabilities$3,308,711
Net Assets$20,186,096

Operations Trend

Revenue, expenses, and net income across loaded years, with this filing highlighted.

$15M$10M$5.0M$0-$5.0M-$10MExpenses 2010: $12,023,7292010Revenue 2011: $8,032,339Expenses 2011: $13,965,618Net Income 2011: -$5,933,2792011Revenue 2017: $5,912,458Expenses 2017: $7,224,684Net Income 2017: -$1,312,2262017Revenue 2018: $5,958,115Expenses 2018: $7,414,227Net Income 2018: -$1,456,1122018Revenue 2019: $8,790,114Expenses 2019: $8,492,655Net Income 2019: $297,4592019Revenue 2020: $5,605,799Expenses 2020: $7,564,949Net Income 2020: -$1,959,1502020Revenue 2021: $6,358,889Expenses 2021: $7,468,165Net Income 2021: -$1,109,2762021Revenue 2022: $8,566,316Expenses 2022: $8,458,746Net Income 2022: $107,5702022Revenue 2023: $9,216,756Expenses 2023: $10,121,975Net Income 2023: -$905,2192023Revenue 2024: $7,061,113Expenses 2024: $11,272,554Net Income 2024: -$4,211,4412024Revenue 2025: $75,497Expenses 2025: $33,244Net Income 2025: $42,2532025

Highlighted filing

2011

Revenue$8,032,339
Expenses$13,965,618
Net Income-$5,933,279
Filing Detail Status

This 2011 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.

Jump To
Filing Snapshot
Filing Period
Jan 1, 2011 to Dec 31, 2011
Mission and Program Overview

Mission

To provide high-value preclinical testing and training services to medical device, biologics, and pharmaceutical developers and manufacturers.

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Filings